Es­pe­ri­on shares surge af­ter ex­ecs say the FDA in­di­cates its LDL pill could be ready to roll in 2019

On Fri­day, an­a­lysts’ bleak as­sess­ment of Am­gen’s car­dio da­ta for its LDL fight­er Repatha caught Es­pe­ri­on’s shares in a broad at­tack that af­flict­ed sev­er­al com­pa­nies fo­cused on cho­les­terol. But this morn­ing the biotech’s stock bound­ed back, and then some, as the com­pa­ny an­nounced that the FDA is will­ing to sign off on an ap­proval for its lead drug — pro­vid­ed it clears LDL low­er­ing goals in a piv­otal study — with­out a car­dio study as a pre­req­ui­site.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER